Articles from Seek Labs

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced progress toward developing the world’s first pan-orthopoxvirus therapeutic, a breakthrough with significant implications for global health security. Orthopoxviruses are part of a group of double-stranded DNA viruses in the Poxviridae family that infect mammals, which include subtypes like human smallpox and Mpox, with new emerging species frequently reported. Orthopoxviruses remain high-concern pathogens due to their epidemic potential, risk of biothreat use, and a re-emergence of Mpox infections worldwide. By leveraging BioSeeker™ and using the company’s novel Programmable Target Ablation Platform (PTAP™), Seek Labs has developed multiplexed guides with pan-orthopoxvirus coverage, enabling development of a programmable CRISPR-based therapeutic.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, announced today that it has joined two federally supported innovation networks: the Investor Catalyst Hub, a regional hub of ARPANET-H launched by the Advanced Research Projects Agency for Health (ARPA-H), and the Rapid Response Partnership Vehicle (RRPV), which supports the Biomedical Advanced Research and Development Authority (BARDA) in accelerating medical countermeasure development. Seek Labs brings its CRISPR-based therapeutics, equipment-free molecular diagnostics, and AI-powered pathogen mapping to applicable opportunities within these networks.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the inclusion of Foot-and-Mouth Disease (FMD) in its BioSeeker™ Global Disease Atlas, advancing the company’s mission to transform genomic data at scale into programmable, CRISPR-based therapeutics. This expansion highlights BioSeeker’s ability to map high-priority veterinary pathogens and accelerate the development of countermeasures for diseases that destabilize food production, disrupt protein supply chains, and strain economic resilience.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB’s waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt’s proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of three of the world’s most persistent mosquito-borne infectious diseases—Chikungunya, West Nile Virus, and Zika—using its proprietary BioSeeker™ discovery engine. These newly mapped targets represent a critical expansion of the company’s Global Disease Atlas and a major step forward in enabling the development of programmable therapeutics with Seek Labs’ PTAP™ platform to combat vector-borne disease threats worldwide.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the inclusion of veterinary pathogens in its Global Disease Atlas, tackling head-on one of global health’s most pressing challenges: safeguarding protein supply chains, which remain exposed to both endemic and emerging biological diseases. These threats directly undermine the resilience of food systems and lead to protein shortages, price volatility, and supply chain destabilization, causing billions in economic losses through culling, trade bans, and supply disruptions. African Swine Fever Virus (ASFV), Capripox (Lumpy Skin Disease, Sheep Pox, Goat Pox), and Classical Swine Fever (CSFV) are among the diseases already mapped by Seek Labs’ BioSeeker™ discovery engine to accelerate the development of targeted therapeutics.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced successful mapping of the Respiratory Syncytial Virus (RSV) genome using its proprietary BioSeeker™ discovery engine to address one of global health’s most persistent and costly viral threats. By pinpointing highly conserved genomic targets, this mapping accelerates development of a programmable CRISPR-based therapeutic on the company’s Programmable Target Ablation Platform (PTAP™). To date, only one antiviral drug has been approved to treat active RSV infection—used sparingly due to cost and significant adverse side effects—highlighting an urgent need for safe, scalable treatments. Seek Labs’ approach enables development of a single pan-RSV therapeutic candidate designed to treat both A and B subtypes.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker™, the company’s proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step toward developing the world’s first programmable antiviral therapeutic for measles, leveraging Seek Labs’ CRISPR-based Programmable Target Ablation Platform (PTAP™).

Seek Labs—a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics—today announced BioSeeker™, a next-generation AI discovery engine redefining how the world identifies and treats disease. It powers Seek Labs’ proprietary Programmable Target Ablation Platform (PTAP), a CRISPR-based system engineered to target and cleave exact genetic sequences required for pathogens to replicate, spread, and cause disease, unlike traditional therapeutic approaches—vaccines, small molecule antivirals, or biological therapies—that attempt to slow, block, or redirect pathogens. BioSeeker rapidly identifies the highest-potential target sites, integrating real-world genomic datasets and proprietary data with powerful computational methods and bioengineering design tools.

Seek Labs, a healthcare innovations company developing diagnostic and therapeutic solutions that have the potential to revolutionize the detection and treatment of diseases, is pleased to announce the appointment of Kim Wirthlin as Chief Strategy Officer, effective March 17, 2025. Wirthlin brings more than 25 years of experience in university leadership, government relations, academic healthcare, and early-stage company development. As Chief Strategy Officer, Wirthlin will lead Seek Labs’ strategic initiatives, strengthening partnerships and expanding the company’s influence as global healthcare innovators.

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and a novel CRISPR-based pharmaceutical technology platform, is excited to announce its sponsorship and participation in the upcoming 2024 Next Generation Dx Summit, hosted by Cambridge Healthtech Institute from August 19-21, 2024, in Washington, D.C. This event brings together global leaders to discuss cutting-edge advancements in diagnostic technologies. Seek Labs’ CEO, Jared Bauer, will be a featured presenter in the Enabling Point-of-Care Diagnostics track on Tuesday, August 20 at 10:00 AM ET. Bauer will discuss the development and optimization of the company’s molecular diagnostic platform, SeekIt™, for point-of-care (POC) applications and reinforce the importance of developing POC diagnostics that meet patient needs. The company will also present two posters at the summit about proprietary nucleic acid extraction and amplification innovations. Attendees can view these posters as part of the Enabling Point-of-Care Diagnostics track from Monday, August 19-Tuesday, August 20.

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based pharmaceutical technology, is pleased to announce the appointment of Dr. Douglas Gladue, PhD as the new Vice President of Veterinary Pharmaceutical Development. Dr. Gladue, an internationally recognized expert in African Swine Fever (ASF) research and development, brings decades of knowledge and experience in ASF vaccine research and development to Seek Labs where he will lead research and development efforts in CRISPR-based veterinary pharmaceutical projects.

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs. The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs. Over half of the CRISPR-treated pigs survived beyond the duration of the trial. Observations and data from both studies reveal compelling outcomes where treatment prolonged lifespans of infected pigs compared to control groups.

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Randy Rasmussen, PhD, to its Board of Directors, effective March 27, 2024. Dr. Rasmussen brings over three decades of experience in molecular diagnostic development and management to Seek Labs that will significantly contribute to the company’s strategic vision for diagnostic technologies for the point of care.

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Michael Paul, PhD to its Board of Directors, effective March 18, 2024. With decades of experience in life sciences innovation, capital formation, and management, Dr. Paul brings industry insight and visionary leadership to accelerate Seek Labs’ growth, strategic initiatives, and research.

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Cindy Dunkle to its Board of Directors, effective February 27, 2024. Dunkle brings decades of life sciences leadership experience and connections that will enhance Seek Labs’ strategic direction and employee-centered approach.

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony brings extensive knowledge and expertise to Seek Labs where she will spearhead the pharmaceutical research division, leading strategic initiatives to advance Seek Labs’ innovation in novel gene therapies.

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced its upcoming participation at the BIO CEO & Investor Conference, which will take place in New York City from February 26-27, 2024. Seek Labs was selected to speak about the Company’s most recent developments as part of the conference’s scheduled programming. The BIO CEO & Investor Conference gathers global industry-leading executives and investors from across the life sciences industry.

Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and pharmaceuticals, today announced the successful completion of a significant expansion at its headquarters. The expansion, aimed at fostering innovation and employee growth, has quadrupled the size of the office space and introduced new facilities to support employee well-being.

Seek Labs, a healthcare innovations company developing next generation molecular diagnostic systems and pharmaceuticals, today publicly announced SeekIt™, a groundbreaking molecular diagnostic testing platform. SeekIt is a complete point-of-care (POC) diagnostic testing platform in a portable, single-use device that brings laboratory-quality testing technology out of a clinic or laboratory and into the hands of patients.